Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

NCT03531827 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

NIH

Sponsor class

Stopped Study was closed for toxicity.

Conditions

Metastatic Castration Resistant Prostate Cancer
Prostate Neoplasms

Interventions

DRUG: enzalutamide
DRUG: CRLX101

Sponsor

National Cancer Institute (NCI)